pirtobrutinib + venetoclax + rituximab

The combination of **pirtobrutinib + venetoclax + rituximab** is an investigational triplet therapy currently studied for relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). - **Pirtobrutinib** is a highly selective, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor that binds BTK even when resistance mutations prevent covalent inhibitors from binding. - **Venetoclax** is a small molecule B-cell lymphoma 2 (BCL-2) inhibitor that induces apoptosis in malignant B cells. - **Rituximab** is a chimeric monoclonal antibody targeting CD20 on B lymphocytes, mediating B-cell lysis. This fixed-duration regimen is designed to offer deep remissions and potentially improve outcomes in heavily pretreated or refractory CLL/SLL patients. The combination is being evaluated in phase 1b, phase 2, and phase 3 clinical trials, with promising early efficacy and tolerability. The primary indication under investigation is **relapsed/refractory CLL/SLL**; new studies are also ongoing in mantle cell lymphoma[1][2][3][7][4][8].

Other names

PVRpirtobrutinib/venetoclax/rituximab